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NEURODEGENERATION-ASSOCIATED INSTABILITY OF RIBOSOMAL DNA 
Justin L. Hallgren 
January 16, 2014 
 
Homologous recombination-mediated instability of the repetitively organized 
ribosomal DNA has been proposed as a mediator of cell senescence in yeast triggering 
the DNA damage response. High individual variability in the content of human ribosomal 
DNA suggests that this genomic region remained relatively unstable throughout 
evolution. Therefore, quantitative real time PCR was used to determine the genomic 
content of ribosomal DNA in post mortem samples of parietal cortex from 14 young and 
9 elderly individuals with no diagnosis of a chronic neurodegenerative/neurological 
disease. In addition, ribosomal DNA content in that brain region was compared between 
10 age-matched control individuals and 10 patients with dementia with Lewy bodies 
which involves neurodegeneration of the cerebral cortex. Probing ribosomal RNA-coding 
regions of ribosomal DNA revealed no effects of aging on the ribosomal DNA content. 
Elevated ribosomal DNA content was observed in Dementia with Lewy Bodies. 
Conversely, in the Dementia with Lewy Bodies pathology-free cerebellum, lower 
genomic content of ribosomal DNA was present in the Dementia with Lewy Bodies 
group. In the parietal cortex, such a Dementia with Lewy Bodies-associated instability of 
ribosomal DNA was not accompanied by any major changes of CpG methylation of the 
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ribosomal DNA promoter. As increased cerebro-cortical ribosomal DNA content was 
previously reported in Alzheimer’s diseases, neurodegeneration appears to be associated 
with instability of ribosomal DNA. The hypothetical origins and consequences of this 
phenomenon are discussed including possibilities that the DNA damage-induced 
recombination destabilizes ribosomal DNA and that differential content of ribosomal 
DNA affects heterochromatin formation, gene expression and/or DNA damage response. 
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 The age related accumulation of DNA damage, and the subsequent genomic 
instability which follows, has been proposed as a mechanism for proliferative senescence, 
cancer, and neurodegeneration, all of which are associated with aging or aging related 
disorders [1-3].  DNA damage is well documented in neurodegeneration and in some 
cases it may be sufficient to cause disease [1, 4].  Moreover, significant increases in 
oxidative DNA damage are known to occur in Alzheimer’s disease, Parkinson’s disease, 
and Dementia with Lewy Bodies [5, 6].  Additionally, multiple congenital diseases 
involving mutations of DNA repair proteins often involve neurodegeneration.  These 
diseases include ataxia with oculomotor apraxia 1, spinocerebellar ataxia with axonal 
neuropathy 1 and xeroderma pigmentosum [1, 4, 7-9].  Moreover, DNA damage is well 
known to induce cell death by a number of mechanisms including inhibition of nucleolar 
transcription and genomic instability [4, 10].   
Homologous recombination is believed to be the preferred DNA damage repair 
mechanism as it produces the highest fidelity, while other repair mechanisms such as 
non-homologous end joining are known to frequently generate single nucleotide 
polymorphism [11].  Homologous recombination utilizes homologous templates, usually 
a sister chromatid, to repair DNA double strand breaks, inter-strand crosslinks, and 
stalled replication forks.  The major limitation is that sister chromatids are only available 
during the late S and G2 phases of the cell cycle [11].  Interestingly in yeast, the 
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mechanisms for increasing ribosomal DNA content have been proposed to be 
homologous recombination with unequal sister chromatid exchange [12]. 
Homologous recombination may potentially act as a double-edged sword in 
regards to genomic stability.  Efficient and accurate DNA repair allows the cells to resist 
replication stress and maintain genomic stability, thus preventing oncogenic 
transformation [13].  Conversely, a growing body of evidence suggests that homologous 
recombination can be a source of genomic instability in response to regulatory failure 
[14-16].  For example, it has been suggested that the Rec Q helicases BLM and WRN, 
whose mutations are linked to Bloom Syndrome and Werner Syndrome respectively, act 
as negative regulators of homologous recombination [17].  Additionally, in Werner 
syndrome, Bloom syndrome, and several subsets of Rothmund-Thomson syndrome, 
which is a third Rec Q linked disease, individuals have a predisposition for cancer [18].  
Moreover in yeast, mutation of the SGS1 helicase creates a hyper recombination 
phenotype which is associated with frequent segmental deletions.  Overexpression of the 
WRN or BLM Rec Q helicases can produce a partial rescue from this hyper 
recombination. [19].  Thus, while homologous recombination is of great importance due 
to its high fidelity DNA repair capabilities, tight regulation is necessary to prevent 
promiscuous potentially oncogenic recombination.   
Recent evidence suggests the dysregulation of homologous recombination in 
neurodegenerative diseases.   The gradual loss of telomeres is a well-documented aspect 
of cellular senescence, but interestingly both expansions and contractions of telomere 
content have been documented in neurodegenerative disease.  Accelerated telomere loss 
has been documented in the leukocytes of patients with Alzheimer’s disease and 
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Dementia with Lewy Bodies [20-23].  Conversely, increased telomere content has been 
documented in the hippocampus of Alzheimer’s disease patients [20].  Moreover, we 
have previously documented an increase in the ribosomal DNA content of parietal- and 
prefrontal- cortex of Alzheimer’s disease donor tissues [24].  Changes in the genomic 
content of highly repetitive sequences, especially those which occur in terminally 
differentiated cells which do not express telomerase, strongly suggest homologous 
recombination as a potential mechanism.   
The tandem repeat arrangement of ribosomal DNA is well known for its relative 
instability compared to other regions of the genome [25-27].  The combination of this 
arrangement and the close physical proximity of all ten arrays inside the nucleolus 
potentially make them hot spots for homologous recombination.  Uneven homologous 
recombination between clusters or within a cluster may lead to expansions or contractions 
of ribosomal DNA content and such a process is common in yeast [12].  In 1972, Bernard 
Strehler proposed the loss of ribosomal DNA copies in post-mitotic cells, such as neurons 
and muscle, as a mechanism of senescence [28].  Strehler proposed that this loss would 
subsequently lead to a deficiency in the ribosomal supply and insufficient levels of 
protein translation.  While his initial results were promising, they were later refuted as 
experimental artifact as subsequent studies could not reproduce these observations [29, 
30].   Moreover, mammalian cell culture based studies of replicative senescence did not 
document changes in ribosomal DNA content [31, 32].   
Cellular growth and maintenance requires enormous amounts of protein synthesis.  
The ribosome is the center of all cellular translation and as such ribosomal quantities are 
linked to the cells protein synthesis capacity [33].  To accommodate the demand for 
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increased protein synthesis, cells have amplified the ribosomal DNA gene which encodes 
for pre-rRNA, a transcript which is processed into the 18S, 5.8S, and 28S ribosomal 
RNAs (rRNAs).  In eukaryotes, ribosomal DNA content is believed to range from 100-
10,000 copies depending on the species [33].  Humans are estimated to have 
approximately 300 copies per haploid genome, which are organized in clusters of long 
tandem arrays on the terminal ends of chromosomes 13, 14, 15, 21 and 22 [26].  
Interestingly, in mature cells only about half of the ribosomal DNA copies are 
transcriptionally active while the other half is epigenetically silenced [34].  This may 
suggest two possibilities.  First, the cellular demand for protein synthesis may vary 
greatly throughout a lifespan.   For example, such a large amount of copies may be 
essential for rapid proliferative growth and early development, but unnecessary upon 
maturity.  Alternatively, excess ribosomal DNA copies may function to allow cells to 
tolerate the loss of damaged copies.  Such a condition may be of great importance for 
post-mitotic neurons which survive for an organism’s entire life span.  Moreover, these 
excess ribosomal DNA copies have evolved to have functions unrelated to ribosomal 
biogenesis, such as regulating chromatin structure, gene expression, and stress response 
[35-39]. 
Alternatively, in yeast the age related loss of ribosomal DNA is known to occur 
and has been proposed as the mechanism behind replicative senescence.  Originally, it 
was thought that ribosomal DNA instability lead to the production of extra chromosomal 
circles a ribosomal DNA cleavage product composed of 8 ribosomal DNA units [40].  It 
was proposed that these ERCs would titrate out the factors necessary for ribosomal 
biogenesis and genome maintenance.  However, more recent work suggests that ERCs 
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are simply a marker of ribosomal DNA instability and that the loss of ribosomal DNA 
itself triggers the DNA damage response [37, 41].  Kobayashi has proposed that 
ribosomal DNA may act as a sink for DNA damage proteins, and thus release them in 
response to ribosomal DNA copy loss [3].  He went on to propose that such a function 
could monitor genomic integrity in a manner somewhat analogous to telomeres [3].    
Previously our lab has documented an increase in ribosomal DNA copy number in 
the parietal cortex tissue of Alzheimer’s disease positive tissue donors using a qPCR 
based approach [24].   Moreover, the increased copy number was associated with an 
increase in ribosomal DNA promoter methylation, which is a marker of inactive copies.  
Interestingly in a murine cell line, decreased epigenetic silencing correlated with loss of 
ribosomal DNA content [38].  This led to two mutually exclusive possibilities.  First, 
increased ribosomal DNA content could be the result of disease associated amplification 
or second, the increased methylation could be preventing an age associated loss of 
ribosomal DNA.  The latter possibility would suggest that the ribosomal DNA stability 
studies conducted in the 1970s and 1980s which disproved Strehler’s hypothesis of age 
related ribosomal DNA loss may have been inaccurate. 
Despite the negative data generated several decades ago, it should be noted that 
the experimental design of these studies utilized a hybridization based competitive 
binding assay and as such did not allow for a high resolution picture of the ribosomal 
DNA gene.  The human ribosomal DNA gene is fairly large with a length of 43kb, of 
which roughly three fourths is the untranscribed intergenic spacer.  The other one fourth  
is composed of the promoter and 3 exons which include the 18S, 5.8S, and 28S rRNAs 
(Fig.  1). The results created by the prior hybridization based approaches do not 
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necessarily exclude segmental losses inside the ribosomal DNA unit.  In support of  
segmental ribosomal DNA loss a more recent study which used a quantitative PCR 
(qPCR)-based approach documented a modest, but still statistically significant, age 
related decrease in 5.8S and 28S ribosomal DNA content, but not 18S [42].  Moreover, a 
study which utilized in situ hybridization with fluorescent probes for 18s and 28s 
unexpectedly demonstrated that in healthy controls approximately one third of ribosomal 
DNA copies are arranged in a head-to-head or tail-to-tail orientation and not strictly in 
tandem arrays as the canonical model suggests [43].  Additionally, they found significant 
heterogeneity in the length of the intergenic spacer.  In fibroblasts obtained from Werner 
patients the frequency of this non-canonical arrangement increased to approximately 50% 
of total ribosomal DNA copies [43].  As Werner syndrome is known to be caused by a 
Req Q helicase mutation, this may suggest homologous recombination is involved in 
these abnormal rearrangements.  Thus, higher resolution techniques have suggested that 
segmental or directional variation of ribosomal DNA units may not be uncommon.   
Independent of age related ribosomal DNA changes, multiple studies suggest that 
ribosomal DNA is relatively unstable compared to other regions of the genome as its 
tandem repeat arrangement potentially makes them hot spots for homologous 
recombination mediated fluctuations in both yeast and higher organisms, including 
humans.  Meiotic ribosomal DNA recombination rates are believed to be as high as 10% 
and this subsequently causes significant heterogeneity in ribosomal DNA content even 
among closely related individuals [44].  In human cells, mitotic ribosomal DNA 
instability is common in both cancer and congenital diseases linked to impaired DNA 
damage repair.  For example, in human cancers approximately 50% of lung and 
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colorectal solid tumors demonstrate ribosomal DNA restructuring [26].  Moreover, this 
restructuring was also seen in fibroblasts from Ataxia Telangiectasia and Bloom 
syndromes, which are known to be caused by mutations in a DNA double strand break 
repair protein ATM and the BLM Rec Q helicase mentioned above [26, 27].  
Surprisingly, mutations in the Rec Q helicase WRN, which is implicated in Werner 
syndrome, did not alter the length of ribosomal DNA clusters [27].  Furthermore, as 
mentioned previously, the methylation status of the ribosomal DNA promoter and 
subsequent heterochromatin formation was directly linked to ribosomal DNA stability in 
a mammalian cell line [38].  Lastly, amphibian and insect oocytes amplify ribosomal 
DNA as extra chromosomal circles presumably to enable exceptionally high rates of 
rRNA synthesis necessary for early development [45-47].  Taken together these facts 
strongly suggest that ribosomal DNA content is unstable under both physiological and 
pathological circumstances in higher organisms. 
 Given our previously described increase in the 18S ribosomal DNA content in 
Alzheimer’s disease parietal cortex tissue and the increased ribosomal DNA promoter 
methylation which accompanied it, we investigated age related segmental changes in 
parietal cortex ribosomal DNA content.  Thus we acquired parietal cortex samples from 
14 young and 9 elderly brain tissue donors, all of which were free of neurological and 
neurodegenerative conditions and probed all 3 ribosomal DNA exons.  Moreover, to 
determine if our prior findings are exclusively a characteristic of Alzheimer’s disease or 
alternatively a general correlate of neurodegeneration, parietal cortex samples from 10 
Dementia with Lewy Bodies tissue donors and 10 healthy age matched controls were 
probed in an identical manner.  Moreover, we acquired cerebellar tissue from Dementia 
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with Lewy Bodies and control subjects to assess if the documented ribosomal DNA 
increases are confined to areas with pathology. 
 Dementia with Lewy Bodies is an age related neurodegenerative disease and is 
the 2nd most common form of dementia in the elderly after Alzheimer’s disease.  The 
major symptom of Dementia with Lewy Bodies is memory loss, but fluctuations in 
alertness, Parkinsonian motor deficits, and visual hallucinations are also common [48].  It 
is associated with the loss of dopaminergic neurons and frequently contains reactive 
gliosis [49, 50].  Pathologically, Dementia with Lewy Bodies is similar to Parkinson’s 
disease as both are classified as synucleinopathies, diseases which are associated with 
intracellular inclusions of aggregated α-synuclein referred to as Lewy Bodies which 
develop in both neurons and glia [48].  Some have speculated that Dementia with Lewy 
Bodies and Parkinson’s disease may be the same disease as they share significant 
symptomatic and pathological overlap.  For example, the major diagnostic difference 
between Dementia with Lewy Bodies and Parkinson’s disease dementia for clinicians is 
only the rate of dementia onset.  Dementia with Lewy Bodies is associated with the 
widespread accumulation of Lewy Body pathology throughout the cortex, including the 
parietal- and prefrontal cortices which were probed in our prior Alzheimer’s disease 
study [51].  The cerebellum is predominately pathology free in Dementia with Lewy 
Bodies.  Thus, Dementia with Lewy Bodies should serve as an ideal specificity control 
for Alzheimer’s disease.  Moreover, synucleinopathies have been documented to contain 
increased amounts of oxidative stress and in particular increased amounts of oxidative 




METHODS AND MATERIALS 
Subjects and sample preparation. For aging studies fresh flash frozen samples of 
parietal cortex (Brodmann areas 39 and 40) were obtained from the NICHD Brain and 
Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD. 
The young donor group consisted of 7 men and 7 women (1-25 years old, median age: 
20); the old donor group consisted of 4 men and 5 women (73-90 years old, median age: 
79). The donors had no prior history of a chronic neurodegenerative- or neurological 
disease. The post mortem intervals were comparable for both groups averaging 7.5 h 
(Post mortem intervals were always less than 14 h). For Dementia with Lewy Bodies 
studies, the donors were participants of the IRB-approved University of Kentucky 
Alzheimer’s Disease Center cohort and were followed for at least 2 years before death 
[53]. The follow up included annual Minimental State Examination as well as 
neurological and physical examinations. The donors had no history of substance abuse, 
head injury, encephalitis, meningitis, epilepsy, or stroke/transient ischemic attack. The 
Minimental State Examination score closest to death was used as an indicator of overall 
cognitive status. During autopsy (usually 5 or less hours after death), tissue samples 
including parietal cortex and cerebellum were processed for neuropathological 
evaluations or flash-frozen in liquid nitrogen and stored at -80°C, as described previously 
[53, 54]. All included Dementia with Lewy Bodies subjects met the clinical and 
histopathological criteria for diagnosis of Dementia with Lewy Bodies [55]. The control 
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subjects received Minimental State Examination scores ≥ 23 with Braak staging at ≤ 2. 
Detailed donor information is presented in Tables 1 and 2.  
 
Analysis of genomic ribosomal DNA content. Genomic qPCR using standard curve 
based analysis was utilized to determine ribosomal DNA content. Amplicons targeting 
18S, 5.8S, and the 28S coding regions of ribosomal DNA were used (Fig 1). For 
normalization, amplicons corresponding to the coding regions of the tRNAK-CTT gene or 
the albumin gene (ALB) were amplified.  
 
Bisulfite mapping of ribosomal DNA promoter methylation was performed as 
described previously [24]. Briefly, two hundred ng of DNA/sample was treated with 
bisulfite to convert unmethylated cytosines to uracil. The ribosomal DNA promoter 
region was PCR-amplified and cloned into the pGEM-T vector. Following bacterial 
transformation, individual clones were isolated and sequenced. Only clones with unique 
methylation patterns were included in the analysis to avoid potential PCR/cloning 
artifacts. Clones with incomplete bisulfite conversion were also discarded. Thus, twenty 
fully converted, and unique clones were analyzed for each individual.  
 
DNA methylation analysis using the methyl-CpG sensitive restriction enzyme HpaII. 
Methylation of the HpaII site located at position -9 relative to the transcription start site 
(CpG #23 of the human ribosomal DNA promoter) was analyzed with a quantitative real-
time PCR of the HpaII-digested genomic DNA as described previously [24] with 
modifications. Importantly, as a reference, the HpaII-digested DNA was used as template 
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to determine the content of an amplicon adjacent to the one with the HpaII site. Such 
normalization resulted in reproducible methylation values as opposed to using a non-
digested DNA with the HpaII amplicon.  
 
Evaluation of methylation effects on qPCR efficiency. An unmethylated DNA 
template for the 5.8S amplicon was obtained by PCR on genomic DNA (primer 
sequences: forward cccgtggtgtgaaacctt, reverse agctagctgcgttcttcatc). 
The PCR product was then in vitro methylated in a buffer containing 6 ng DNA/µL, 0.16 
mM S-adenosylmethionine and 0.2 units M.SssI/µL (New England Biolabs) at 37°C for 2 
hours followed by M.SssI inactivation at 65°C for 20 minutes. Methylated and 
unmethylated templates were used for qPCR with the 5.8S amplicon primers. To verify 
the extent of methylation, both methylated and unmethylated templates were incubated 
with the methyl sensitive restriction enzyme HpaII. Template resistance to HpaII was 
determined by qPCR.  
 
Statistical analysis was performed using the non-parametric Kruskal-Wallis one way 
ANOVA and linear regression fitting. In addition, comparisons of individual ribosomal 
DNA methylation sites were accomplished using a modified significance analysis of 
microarrays (SAM), as reported previously [24]. 
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Table 1. Young and old donors of the parietal cortex samples that were used for the 
aging studies. 









2 10 Male 
15 9 Female 
16 7 Male 
18 8 Female 
19 7 Female 
20 6 Male  
20 5 Male  
21 7 Male 
22 7 Male 
22 10 Female 
24 9 Female 
24 7 Female 
24 9 Male 
25 4 Female 





73 13 Female 
76 3 Male 
76 3 Female 
77 8 Female 
79 5 Male 
79 10 Male 
88 8 Female 
89 14 Male 
90 4 Female 
1PMI, post mortem interval 
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Table 2. Control and Dementia with Lewy Bodies donors of the parietal cortex and 
the cerebellum samples that were used for the Dementia with Lewy Body studies. 
Group Age (years) PMI (h)1 Sex Parietal cortex Cerebellum 
Control 77 3.5 Male + Unavailable 
81 2 Male + Unavailable 
87 2.4 Male + Unavailable 
82 2.1 Male + Unavailable 
85 2.5 Female + + 
90 2 Female + + 
79 1.8 Female + + 
78 1.2 Male + + 
81 2.8 Male + + 
96 2.1 Female + + 
86 2.5 Female Not included + 
90 3.8 Female Not included + 
80 2.5 Female Not included + 
95 2.8 Female Not included + 
DLB2 78 2.5 Male + + 
78 3.8 Male + + 
81 2.5 Male + + 
72 2.8 Male + + 
65 9.5 Male + + 
87 2 Female + + 
68 3.8 Male + + 
90 2.5 Female + + 
82 2.3 Male + + 
91 10.5 Female + + 
1PMI, post mortem interval, 2DLB, Dementia with Lewy Bodies 
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Table 3.  qPCR primers used for aging, Dementia with Lewy Bodies, and HPAII 
based methylation Studies. 
Primer Set Direction Sequence 5’ to 3’ 
18S Forward agcctgagaaacggctacca 
Reverse ggtcgggagtgggtaatttgc 
5.8S Forward gaggcaaccccctctcctctt 
Reverse gagccgagtgatccaccgcta 
28S Forward gacctcagatcagaggtggcga 
Reverse ttcactcgccgttactgagggaat 
tRNAK-ctt Forward ctagctcagtcggtagagcatg 
Reverse ccaacgtggggctcgaac 
ALB Forward cggcggcgggcggcgcgggctgggcggaaatgctgcacagaatccttg 
Reverse gcccggcccgccgcgcccgtcccgccggaaaagcatggtcgcctgtt 










Stability of the cerebro-cortical ribosomal DNA copy number in aging. To assess the 
effects of aging on ribosomal DNA copy number in the brain, genomic DNA was isolated 
from post mortem parietal cortex samples that were collected from two groups of donors. 
The young donor group consisted of 14 individuals with a median age of 201.6 (range 
1-25, Table 1). The old donor group included 9 individuals with a median age of 792.1 
(range 73-90, Table 1). None of the donors were known to suffer from a chronic 
neurodegenerative and/or neurological disease. The genomic content of 18S- and 28S 
rRNA coding regions of ribosomal DNA was analyzed by a qPCR assay (Fig. 1). For 
normalization, a coding region of the multi-copy gene tRNAK-ctt was used. There are 17 
almost identical copies of this gene in the haploid human genome. However, in contrast 
to ribosomal DNA, they are not clustered together [56] and therefore, are less likely than 
ribosomal DNA to undergo recombination-associated instability.  
As the investigated ribosomal DNA regions are physically linked, a direct correlation 
between their genomic content for each analyzed sample is expected (Fig. 1). Indeed, the 
individual values obtained for the 18S- and the 28S amplicons were strongly correlated 
fitting to a linear model of a direct correlation (Fig. 2A, a=0.7327, R2=0.8103). These 
results support accuracy of the applied qPCR methodology for determination of the 
genomic ribosomal DNA content. 
However, genomic content of 18S- and 28S- regions of ribosomal DNA did not 
significantly differ between the young- and the old subjects (Fig. 2B, C). Usage of a 
16 
 
coding region of the albumin gene (ALB) as an alternative genomic reference produced 
similar results (Fig. 2D). Therefore, in the cerebral cortex, genomic content of ribosomal 
DNA appears to be stable throughout the lifespan.  
 
Dementia with Lewy Bodies-associated instability of brain ribosomal DNA. To 
assess whether aging-related neurodegeneration affects genomic ribosomal DNA content 
in the brain, post mortem parietal cortex samples from ten patients who were diagnosed 
with Dementia with Lewy Bodies were analyzed (Table 2). The control group included 
ten age-matched individuals who died of non-neurological diseases and whose brains did 
not display any evidence of neurodegeneration (Table 2). Similar to the midbrain-focused 
Parkinson’s disease, Dementia with Lewy Bodies is a form of a synucleinopathy [57, 58]. 
Their common characteristic is the presence of intracytoplasmic -synuclein-containing 
inclusions, the Lewy Bodies. In addition, Dementia with Lewy Bodies is associated with 
neuronal atrophy, neuronal death and reactive gliosis in the cerebral cortex including the 
parietal region [57]. Oxidative damage of macromolecules including DNA is observed in 
both conditions [5, 59]. Hence, Dementia with Lewy Bodies and Parkinson’s disease may 
represent a similar pathological process that affects different areas of the brain.  
Three ribosomal DNA coding regions were analyzed including probes corresponding 
to the 18S-, 5.8S-, and 28S exons. As expected for a tight physical linkage, the Dementia 
with Lewy Bodies- and the control group-derived individual values obtained with these 
probes correlated with each other fitting a linear model of direct correlation (28S(18S), 
y=1.7416*x-0.6165, R2=0.8495; 5.8S(18S), y=1.4776*x-0.4126, R2=0.8957; 28S(5.8S), 
y=1.1008*x-0.0133, R2=0.8274). Interestingly, genomic content of ribosomal DNA was 
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higher in Dementia with Lewy Bodies. In this group, the 18S-, 5.8S-, and 28S probes 
revealed ribosomal DNA content that was 1.6-, 2.0-, and 2.3 fold controls respectively 
(Kruskal-Wallis  ANOVA, p<0.01, Fig. 3A-C). Similar results were obtained when ALB 
was used as an alternative genomic reference (Fig. 3D). To determine whether this 
Dementia with Lewy Bodies-associated effect on ribosomal DNA content was directly 
related to pathological changes in the cortex, samples from the Dementia with Lewy 
Bodies pathology-free cerebellum were analyzed. In samples from this structure, direct 
correlations between individual values for various ribosomal DNA probes were observed 
confirming accuracy of our determinations (data not shown). Surprisingly, in the 
cerebellum, ribosomal DNA content was lower in the Dementia with Lewy Bodies group. 
Significant decreases of 0.55- and 0.42 fold control were observed for the 5.8S- and 28S 
probes, respectively (Kruskal-Wallis ANOVA, p<0.01, Fig. 4). While the 18S probe did 
not detect significant differences between the two groups, the genomic 18S content also 
showed a downward trend in Dementia with Lewy Bodies (Fig. 4). Therefore, Dementia 
with Lewy Bodies appears to be associated with instability of brain ribosomal DNA.  
 
Effects of Dementia with Lewy Bodies on methylation of the ribosomal DNA 
promoter region. At least in cancer cell lines, amplification of ribosomal DNA may be 
associated with CpG hypermethylation [60]. As CpG methylation of the ribosomal DNA 
is associated with epigenetic silencing of ribosomal DNA copies a combination of 
amplification and hypermethylation may help to keep the number of active ribosomal 
DNA copies constant [34]. Moreover, epigenetic silencing of ribosomal DNA may 
stabilize the inactive genes preventing recombination; conversely, de-silencing may have 
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an opposite effect [3, 38]. Thus, methylation of the ribosomal DNA promoter region was 
analyzed in the parietal cortex of the Dementia with Lewy Bodies- and control groups 
using the CpG methylation-sensitive restriction endonuclease HpaII or bisulfite 
sequencing. Methylation of the ribosomal DNA promoter was similar in the Dementia 
with Lewy Bodies- and the control group (Fig. 5). Therefore, in the Dementia with Lewy 
Bodies pathology-affected cerebral cortex, ribosomal DNA amplification is not 
associated with changes in CpG methylation of the ribosomal DNA promoter.  
 
Effects of template methylation on qPCR efficiency. Methylation of ribosomal DNA is 
observed not only in the promoter region but also in the rRNA-coding exons that have 
been targeted for qPCR-based ribosomal DNA quantification. Therefore a possibility 
exists that the apparent Dementia with Lewy Bodies-associated changes in ribosomal 
DNA content are due to altered methyl-CpG content in those regions if methylation 
affects qPCR amplification efficiency. To exclude such a possibility, non-methylated 
ribosomal DNA fragment containing the 5.8S amplicon template was produced by PCR. 
As the 5.8S amplicon contains 19 CpG sites including 3 in the reverse primer target 
sequence methylated template was generated in vitro using a non-selective CpG DNA 
methyltransferase M.SssI (Fig. 6). As compared to the unmethylated template, 
methylation only slightly increased qPCR efficiency resulting in about 10% 
overestimation of the template content. Therefore, even dramatic changes in CpG 
methylation of the ribosomal DNA templates are unlikely to explain up to 130%- 
increases or decreases of ribosomal DNA content that were observed between control and 
Dementia with Lewy Bodies samples. 
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DISCUSSION AND CONCLUSIONS 
In this study, we probed for changes in ribosomal DNA content in the brain of old 
vs young subjects and Dementia wit Lewy Bodies patients vs. controls using a qPCR 
based approach. No difference was detected in the parietal cortex ribosomal DNA content 
of young and old individuals. Our results are in agreement with a study which attempted 
to address this question using a hybridization based approach. Significant increases in 
ribosomal DNA content were detected in the parietal cortex of Dementia with Lewy 
Bodies individuals compared to age matched controls with increases ranging from 
approximately 1.5 to 2.2 fold. The ribosomal DNA content of the cerebellum, a region 
which does not show pathological changes in Dementia with Lewy Bodies also contained 
altered ribosomal DNA content, however the direction of change was unexpectedly 
opposite that of the parietal cortex with a decrease of approximately 50% in two of the 
three probed regions.  
Our prior Alzheimer’s disease study produced similar results for the parietal 
cortex as both Dementia with Lewy Bodies and Alzheimer’s disease contained elevated 
ribosomal DNA content [24]. Moreover, the magnitude of 18S increase, approximately 
50%, was similar to what has been documented in mild cognitive impairment and late 
stage Alzheimer’s disease which contained increases of 50% and 69%, respectively. In 
contrast, the Dementia with Lewy Bodies’ cerebellum contained a significant decrease in 
ribosomal DNA content, a finding which was not apparent in Alzheimer’s disease. 
However, it is important to note that this decrease was documented in the 5.8S and 28S 
20 
 
ribosomal DNA regions which were not probed in our prior Alzheimer’s disease study. 
The 18S region trended down in Dementia with Lewy Bodies but did not reach statistical 
significance. Thus, comparing the Dementia with Lewy Bodies and Alzheimer’s disease 
cerebellum is at least partially inconclusive. Interestingly, a similar trend has been 
documented in the genomic content of another highly repetitive sequence, the telomere. 
In both Alzheimer’s disease and Dementia with Lewy Bodies telomere length was 
decreased in peripheral blood leukocytes, and, at least in the case of Alzheimer’s disease, 
increased in the hippocampus, a brain structure directly affected by Alzheimer’s disease 
pathology [20-22]. 
 It is important to note that all data obtained in this study are based on genomic 
DNA which was extracted from tissue containing a mixed population of cells. Thus, it is 
unclear which cell type or types are contributing to these findings. As homologous 
recombination is believed to be the major mechanism behind ribosomal DNA instability 
and readily occurs during both mitosis and meiosis, this suggests inappropriate activation 
of homologous recombination is occurring in cycling cycles. [44].  Recent literature 
suggests this may not be the only possibility for our findings.   We propose three 
potential explanations.  
 First, this phenomenon could be occurring in cycling cells. This may suggest our 
findings are the result of reactive gliosis, a condition which is involved in both 
Alzheimer’s disease and Dementia with Lewy Bodies [61, 62]. Reactive gliosis involves 
mitosis and the rapid proliferation of glia, thus allowing homologous recombination to 
occur. Theoretically, expansion of ribosomal DNA in reactive glia could aid in their 
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ability to rapidly proliferate. A similar phenomenon is known to occur in amphibian and 
insect oocytes [45-47].  
 A second potential explanation is that homologous recombination occurs in 
response to reactivation of the cell cycle in post-mitotic neurons. Multiple studies have 
documented at least partial cell cycle reactivation in Alzheimer’s disease pathology 
associated areas [63-65]. Proteins from all phases of the cell cycle have been shown to be 
increased in Alzheimer’s disease. Moreover, the frequency of aneuploidy has also been 
shown to be increased in Alzheimer’s disease [66]. Such a condition could potentially be 
sufficient for homologous recombination to occur.  
 Lastly, canonical homologous recombination may not be necessary for 
fluctuations in ribosomal DNA copy number. Interestingly, emerging data have identified 
homologous recombination-like activity in post-mitotic cells [67, 68]. In these cells, UV 
radiation induced double strand breaks which were repaired using a mechanism that 
involved short segmental contact between homologous chromosomes in a transcription- 
and ATM- dependent manner.  Theoretically, such a repair mechanism could be 
sufficient to produce effects similar to canonical homologous recombination. Moreover, 
the unique repetitive nature of the ribosomal DNA and the general structure of the 
nucleolus may allow for recombination in the absence of mitosis. The cell’s 600 copies of 
ribosomal DNA, which are arranged as tandem arrays on 5 separate chromosomes, are all 
in close physical proximity due to their nucleolar localization. Such an atypical 
orientation and the relatively high rates of transcription which occur in this region may 




 While the effects of altered ribosomal DNA content in the human brain are 
unclear, findings from lesser species and mammalian cell lines may potentially provide 
insight. Surprisingly, the rate of ribosomal biogenesis may not be subject to large 
alterations under the documented circumstances.  It is known that most multicellular 
species contain a large excess of ribosomal DNA copies of which a large percentage is 
epigenetically silenced [69]. Thus, an expansion of ribosomal DNA copies would most 
likely add to this epigenetically silenced pool and cause little, if any, alterations in the 
rate of ribosomal biogenesis. Moreover, cells appear capable of withstanding limited 
ribosomal DNA loss. Germ line deletions of significant ribosomal DNA quantities in 
both flies and chickens still produced viable organisms [70, 71]. For example in the 
chicken study, embryos with 66% of the normal ribosomal DNA content grew and 
developed as expected [70]. Thus, a portion of the cellular ribosomal DNA content is 
unnecessary for ribosome synthesis even during the organism’s most demanding periods 
of growth. Taken together, these reports suggest that any potentially detrimental effects 
of ribosomal DNA copy loss are potentially related to functions other than ribosomal 
biogenesis. 
 Interestingly, in lower organisms, manipulation of ribosomal DNA content has 
identified several non-coding functions. In the aforementioned fly studies, ribosomal 
DNA variation directly influenced heterochromatin content [35]. Moreover, in a mouse 
cell line, loss of the nucleolar silencing complex component TIP5 lead to a decrease in 
both heterochromatin content at major- and micro- satellite DNA and loss of ribosomal 
DNA content [38]. Taken together, such findings suggest that ribosomal DNA instability 
may affect mammalian heterochromatin content. Moreover in ribosomal DNA deficient 
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flies, changes in euchromatin and gene expression changes were detected [36]. 
Furthermore, clusters of genes linked to both mitochondrial function and lipid 
metabolism were prominent in the population of altered genes [36]. Interestingly, 
alterations in both of these areas are common to both Alzheimer’s disease and Dementia 
with Lewy Bodies [52, 72-74].   
 In yeast it has been proposed that silent ribosomal DNA copies function as a sink 
for mediators of the DNA damage response. Kobayashi proposed a model in which 
ribosomal DNA loss, which is known to be associated with replicative senescence, would 
release DNA damage response mediators in a manner analogous to telomere shortening 
triggering the DNA damage response [3]. Alternatively, increased ribosomal DNA 
content could potentially raise the threshold for DNA damage response activation. In 
support of Kobayashi’s theory, it was demonstrated that yeast with larger ribosomal DNA 
content were more resistant to the DNA damaging agent methyl methanesulfonate than 
those with less ribosomal DNA content. While this possibility has not been addressed in 
mammalian cells, nucleolar sequestration of other stress mediators is known.  Heat Shock 
Protein 70, Murine Double Minute 2, and the Von Hippel Lindau protein have been 
documented to be sequestered in the nucleolus via their affinity for non-coding RNAs 
generated from the intergenic spacer region of the ribosomal DNA unit [39]. Therefore, 
changes in ribosomal DNA content may affect the cellular stress response. 
 While more work needs to be done to identify the consequences of ribosomal 
DNA instability in the human brain, we propose a working model based on the effects of 
altered ribosomal DNA documented in the literature (Fig.7). We propose DNA damage 
induced genomic instability as a general component of the degenerating brain. Under 
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these conditions, ribosomal DNA content would be disproportionally affected due to its 
tandem array arrangement, the high rate of ribosomal DNA transcription, and the 
physical proximately of all 10 ribosomal DNA arrays. In this model homologous 
recombination or “homologous recombination like” activity would produce instability in 
ribosomal DNA content. This would ultimately alter heterochromatin levels, euchromatin 
gene expression, and the DNA damage response. Increases in ribosomal DNA content 
would increase the level of heterochromatin, increase ribosomal DNA’s ability to 
influence euchromatin gene expression, and increase DNA damage response resistance. 
Conversely, loss of ribosomal DNA would produce the opposite effect.  We propose 
that genomic instability is induced by DNA damage.   Additionally, the application of a 
selection pressure, such as the enhanced DNA damage which is common to the Dementia 
with Lewy Bodies and Alzheimer’s disease parietal cortex, would select for increased 
ribosomal DNA content and promote cell survival. Thus in the Dementia with Lewy 
Bodies cortex, which experiences significantly larger levels of oxidative stress and 
synucleinopathy, the magnitude of DNA damage would be large enough to select for 
increased quantities of DNA. In the case of the Dementia with Lewy Bodies cerebellum, 
low level potentially undetectable DNA damage would still induce genomic instability.  
However, no such selection pressure would exist and genomic instability would present 
as a loss of ribosomal DNA. Moreover, neurodegeneration associated cell loss would 
remove less resilient cells thus further enriching the total population with cells containing 
higher ribosomal DNA content.  
 In summary, we have not detected any age related changes in ribosomal DNA 
content. However, we have identified a second neurodegenerative disease, Dementia with 
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Lewy Bodies, with increased ribosomal DNA content in the parietal cortex. Moreover, 
we unexpectedly documented decreased ribosomal DNA content in the pathology free 
cerebellum specifically for the 5.8S and 28S segments. Therefore, we propose that 
genomic instability is present in the degenerating brain.
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Figure 1. The qPCR-based assay to determine the genomic content of ribosomal 
DNA. The ribosomal DNA copies are organized as long tandem repeats located on five 
acrocentric chromosomes. Each copy consists of the ribosomal RNA gene and the 
intergenic spacer. Each ribosomal RNA gene includes a Pol1-dependent promoter and 
exons that correspond to 18S-, 5.8S- and 28S ribosomal RNAs. They are separated by 
introns (5’ETS, ITS1, ITS2 and 3’ETS). The positions of the analyzed ribosomal DNA 






Figure 2. Effects of age on the cerebro-cortical content of ribosomal DNA. Genomic 
ribosomal DNA content was quantified in post mortem samples of the parietal cortex 
from young- and old individuals without any neurodegenerative conditions (n=14, 
median age 20, and n=9, median age 79, respectively). The 18S- and 28S- amplicons 
were used for ribosomal DNA content determinations; the reference genes are indicated. 
For each amplicon, the ribosomal DNA content was normalized to average value of 
young individuals. A, Regression analysis of individual values of ribosomal DNA content 
as determined with 18S- or 28S probes. As expected for a close physical linkage between 
these genomic templates, a direct correlation is present supporting validity of the qPCR 
assay. Filled or opened diamonds indicate young or old individuals, respectively. B-D, 
Content of ribosomal DNA is similar in young- and old individuals. Individual values are 
depicted by squares; mean values are indicated by the lines intersecting the error bars 





Figure 3. Increased ribosomal DNA content in the Dementia with Lewy Bodies 
parietal cortex. Genomic ribosomal DNA content was quantified in post mortem 
samples of the parietal cortex from Dementia with Lewy Bodies- and age-matched 
control individuals without any neurodegenerative conditions (n=10 each). The 18S-, 
5.8S- and 28S amplicons were used for the determinations; the reference genes are 
indicated. Regression analysis of individual values for pairs of ribosomal DNA amplicons 
revealed strong correlations similar to those in Fig. 2A (see the Results section for more 
details).In the Dementia with Lewy Bodies group, significant increases of ribosomal 
DNA content were detected using the 18S/tRNAK-ctt (A), 5.8S/tRNAK-ctt (B), 28S/tRNAK-ctt 
(C) and 18S/ALB  (D) ratios. Individual values are depicted by squares; mean values are 






Figure 4. Decreased ribosomal DNA content in the Dementia with Lewy Bodies 
cerebellum. Genomic ribosomal DNA content was quantified in post mortem samples of 
the cerebellum from 10 Dementia with Lewy Bodies- and 10 aged-matched control 
individuals. Regression analysis of individual values for pairs of ribosomal DNA 
amplicons revealed strong correlations similar to those in Fig. 2A (data not shown). 
While a downward trend was observed for the 18S amplicon (A), the 5.8S- and the 28S 
probes revealed significant decreases of ribosomal DNA content in Dementia with Lewy 
Bodies samples (B-C). Individual values are depicted by squares; mean values are 








Figure 5. Similar methyl-cytosine content of the ribosomal DNA promoter region in 
the control- and Dementia with Lewy Bodies parietal cortex. A, Methylation of the 
ribosomal DNA promoter CpG#23 (position -9 from the transcription start site) content 
was determined using a methylation-sensitive enzyme HpaII and qPCR. B-C, 
Methylation of all 26 CpG sites within the human ribosomal DNA promoter region 
(positions -186 to +26) was investigated using bisulfate sequencing. B, Average CpG 
methylation in the ribosomal DNA promoter. C, Effect of Dementia with Lewy Bodies 
on distribution of CpG methylation across the ribosomal DNA promoter. The data 
represent averages ±SEM from 10 Dementia with Lewy Bodies- and 10 control- 
individuals. Individual values are depicted by squares; mean values are indicated by the 
lines intersecting the error bars. In A and B, p values of the Kruskal-Wallis ANOVA are 
shown; in C, *, p<0.05 (SAM statistics). Although CpG#7 and 17 appeared hyper 
methylated in Dementia with Lewy Bodies, the overall trend of CpG methylation across 
the 26 ribosomal DNA promoter CpGs was not significantly affected by Dementia with 







Figure 6. Effects of template methylation on qPCR efficiency. A, PCR on genomic 
DNA was used to produce an unmethylated DNA fragment including a template for the 
5.8S qPCR amplicon that revealed ribosomal DNA instability in Dementia with Lewy 
Bodies (red box, qPCR primers indicated by red arrows, PCR primers indicated by black 
arrows). DNA was then in vitro methylated with M.SssI DNA methyltransferase that 
indiscriminately targets all CpG sites. Note presence of multiple CpGs in the 5.8S 
amplicon (opened and filled circles correspond to CpGs or methyl-CpGs, respectively; 
one of the CpGs is a part of an HpaII site). B, Methylation of a CpG that was part of an 
HpaII site was confirmed using HpaII-qPCR assay. When methylated DNA fragment was 
used as a template for 5.8S qPCR, ribosomal DNA content was overestimated by just 
10% as compared to unmethylated template. Hence, differential methylation of ribosomal 
DNA templates of the qPCR amplicons is unlikely to account for Dementia with Lewy 
Bodies-associated changes in ribosomal DNA content. Data represent two independent 





Figure 7. A hypothetical model summarizing possible causes and consequences of 
ribosomal DNA instability. The DNA damage-stimulated homologous recombination is 
a likely cause of ribosomal DNA instability in the degenerating brain. The moderate 
changes in ribosomal DNA copy number as those reported here are not expected to 
significantly affect ribosomal biogenesis. Instead, ribosomal biogenesis-independent 
functions of ribosomal DNA may be affected including control of the DNA damage 
response, maintenance of heterochromatin, and expression regulation of the non-
ribosomal RNA genes that are located in the euchromatin. One can speculate that higher 
content of ribosomal DNA may support cell survival by suppressing the DNA damage 
response, stabilizing chromatin and stronger regulatory control of the euchromatic genes. 
Conversely, lower ribosomal DNA content may have opposite effects on cell sensitivity 
to DNA damage as well as other forms of stress by enhancing the DNA damage response, 
reducing control over euchromatin gene expression and destabilizing the chromatin 
architecture. Thus, ribosomal DNA amplification in the degenerating regions of the 
Dementia with Lewy Bodies- or Alzheimer’s- disease brain may be a consequence of 
increased genotoxic stress. In turn, cells with the higher genomic content of ribosomal 
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